Improvement of a Predictive Model of Castration-Resistant Prostate Cancer: Functional Genetic Variants in TGFβ1 Signaling Pathway Modulation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Teixeira, Ana L ^a,b   Gomes, Mónica ^a,b   Nogueira, Augusto ^a   Azevedo, Andreia S ^a   Assis, Joana ^a   Dias, Francisca ^a,b   Santos, Juliana I ^a,b   Lobo, Francisco ^a   Morais, António ^a   Maurício, Joaquina ^a   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^d Portuguese League Against Cancer (Norte)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD7 GENE; TGFBR2 GENE;

EID: 84881245194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072419     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
2. Hou X, Flaig TW, (2012) Redefining hormone sensitive disease in advanced prostate cancer. Adv Urol, 2012(2012): 978531. PubMed: 22461790.
3. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, et al. (2011) Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17: 6218-6228. doi:10.1158/1078-0432.CCR-11-1548. PubMed: 21844010.
4. Aggarwal R, Ryan CJ, (2011) Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 16: 264-275. doi:10.1634/theoncologist.2010-0216. PubMed: 21339259.
5. Bierie B, [!(surname)!], (2010) Transforming growth factor beta (TGF-B) and inflammation in cancer. Cytokine Growth Factor Rev 21: 49-59. doi:10.1016/j.cytogfr.2009.11.008. PubMed: 20018551.
6. Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, et al. (2004) Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 25: 237-240. PubMed: 14604900.
7. Wikström P, Damber J, Bergh A, (2001) Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech 52: 411-419. doi:10.1002/1097-0029(20010215)52:4. PubMed: 11170300.
8. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, et al. (2007) TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7: 156. doi:10.1186/1471-2407-7-156. PubMed: 17692120.
9. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, et al. (2007) The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117: 206-217. doi:10.1172/JCI29293. PubMed: 17160136.
10. Rojas A, Padidam M, Cress D, Grady WM, (2009) TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim Biophys Acta 1793: 1165-1173. doi:10.1016/j.bbamcr.2009.02.001. PubMed: 19339207.
11. Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, et al. (2006) Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66: 9837-9844. doi:10.1158/0008-5472.CAN-06-0890. PubMed: 17047044.
12. Seijo ER, Song H, Lynch MA, Jennings R, Qong X, et al. (2001) Identification of genetic alterations in the TGFβ type II receptor gene promoter. Mutat Res 483: 19-26. doi:10.1016/S0027-5107(01)00217-2. PubMed: 11600128.
13. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, et al. (2009) Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J 9: 341-346. doi:10.1038/tpj.2009.20. PubMed: 19488063.
14. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583. doi:10.1016/j.eururo.2011.01.025. PubMed: 21315502.
15. Harrell FE Jr., Lee KL, Mark DB, (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387. doi:10.1002/(SICI)1097-0258(19960229)15:4. PubMed: 8668867.
16. Aschelter AM, [!(surname)!], Caporelloand P, Marchetti P, (2012) Genomicandepigenomicalterationsinprostatecancer. Front Endocrinology 3: 1-9.
17. Aschelter AM, Giacinti S, Caporello P, Marchetti P, (2012) Genomic and epigenomic alterations in prostate cancer. Front Endocrinology 3: 128-. PubMed: 23133437.
18. Connolly EC, Freimuth J, Akhurst RJ, (2012) Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 8: 964-978. PubMed: 22811618.
19. Kim SJ, Im YH, Markowitz SD, Bang YJ, (2000) Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 11: 159-168. doi:10.1016/S1359-6101(99)00039-8. PubMed: 10708963.
20. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851. doi:10.1126/science.1090922. PubMed: 14764882.
21. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL, (2008) Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 6: 1521-1533. doi:10.1158/1541-7786.MCR-07-2203. PubMed: 18922968.
22. Grady WM, Willis JE, Trobridge P, Romero-Gallo J, Munoz N, et al. (2006) Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 118: 600-608. doi:10.1002/ijc.21399. PubMed: 16108056.
23. Lu B, Zhou YN, Li Q, Wu ZQ, Zhang ZY, et al. (2009) Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer] 28. Zheng: Ai. pp. pp. 538-542.
24. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A, (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29. doi:10.1002/(SICI)1097-0045(19980915)37:1. PubMed: 9721065.
25. Buscaglia LE, Li Y, (2011) Apoptosis and the target genes of microRNA-21. Chin J Cancer 30: 371-380. doi:10.5732/cjc.30.0371. PubMed: 21627859.
26. Bruckheimer EM, Kyprianou N, (2001) Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 142: 2419-2426. doi:10.1210/en.142.6.2419. PubMed: 11356690.
27. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, et al. (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 14: 3367-3371. doi:10.1158/1078-0432.CCR-07-5119. PubMed: 18519765.
28. Jin G, Deng Y, Miao R, Hu Z, Zhou Y, et al. (2008) TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol 134: 345-351. doi:10.1007/s00432-007-0290-1. PubMed: 17680270.
29. Jin G, Wang L, Chen W, Hu Z, Zhou Y, et al. (2007) Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer 120: 1330-1335. doi:10.1002/ijc.22443. PubMed: 17187359.
30. Guo W, Dong Z, Guo Y, Chen Z, Yang Z, et al. (2012) Association of polymorphisms in transforming growth factor-beta receptors with susceptibility to gastric cardia adenocarcinoma. Mol Biol Rep 39: 4301-4309. doi:10.1007/s11033-011-1217-0. PubMed: 21785915.
31. Xu L, Zeng Z, Chen B, Wu X, Yu J, et al. (2011) Association between the TGFB1-509C/T and TGFBR2-875A/G polymorphisms and gastric cancer: a case-control study. Oncol Lett 2: 371-377. PubMed: 22866090.
32. Zhang M, Guo LL, Cheng Z, Liu RY, Lu Y, et al. (2011) A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER(+), PR(+), ER(+)PR(+) and HER2(-) expression in women. Oncol Lett 2: 653-658. PubMed: 22848244.
33. Choe B-K, Kim S, Park H, Park H-K, Kwon K, et al. (2012) Polymorphisms of TGFBR2 contribute to the progression of papillary thyroid carcinoma. Molecular Cell Toxicology 8: 1-8. doi:10.1007/s13273-012-0001-0.
34. Jin Q, Hemminki K, Grzybowska E, Klaes R, Söderberg M, et al. (2004) Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112: 94-99. doi:10.1002/ijc.20370. PubMed: 15305380.